Immunological results from a study with Diamyd® will be presented in April

Diamyd Medical (Nasdaq Stockholm First North Ticker: DMYD B) informs that
immunological results from DIABGAD, one of five ongoing studies with the
diabetes vaccine Diamyd®, will be presented at an international diabetes
congress (IDS) held in Munich on April 12 to 16, 2015.
Immunological findings from a study with Diamyd®, DIABGAD, will be presented by
Professor Johnny Ludvigsson at an international diabetes meeting held in Munich
on April 12-16, 2015. Preparations for the code break are ongoing and the code
will be broken and the results analyzed shortly before the presentation. In the
study, which is one of five ongoing studies with Diamyd®, Diamyd® plus vitamin D
and ibuprofen is tested in order to strengthen the 16 percent (p = 0.10) average
effect Diamyd®, as monotherapy, demonstrated compared to placebo in a European
Phase III study.

Among the speakers at the congress are several members of Diamyd Medical's
Scientific Advisory Board; Professors Mark Atkinson, Åke Lernmark, Bart Roep and
David Leslie. In addition, Anders Essen-Möller from Diamyd Medical is invited to
give his views on the development of a diabetes vaccine from an industrial
perspective.

To be noted is that Craig Beam, Professor of Biostatistics, Kalamazoo, US, is
invited to discuss the Bayesian statistical methods with which he recently
reanalyzed results from three studies with the diabetes vaccine Diamyd®
comprising more than 500 type 1 diabetes patients. The conclusion of the
analysis of the European Phase III study is that the diabetes vaccine Diamyd® is
effective with a probability of 97%. Prominent diabetes researchers who are co
-authors to Craig Beam’s analysis results for Diamyd® include Jerry Palmer,
Diane Wherrett, Kevin Herold, Johnny Ludvigsson, Colleen MacCallum and
researchers within the Type 1 Diabetes TrialNet Study Group.

The immunological results to be presented are from 6 months after the patients
were enrolled in the study. The total number of patients is 64, divided into
four groups: a) Diamyd® in combination with ibuprofen and vitamin D, b) Diamyd®
in combination with vitamin D, c) Diamyd® in double dose in combination with
vitamin D; d) Placebo (inactive substance).

“We hope that the six-month results will show that this autoimmune disease is
now modulated in the right direction,” says Anders Essen-Möller, President and
CEO of Diamyd Medical. “If so, we have good hope that this, at 15 months, will
provide a long-term positive effect on metabolic parameters such as the own
ability to produce insulin. The last patient will perform the 15 month visit in
September 2015 and metabolic results from the study are planned to be presented
by the end of this year.”

About the diabetes vaccine Diamyd®
Type 1 diabetes is a devastating disease which requires daily treatment with
insulin to sustain life. The importance of finding a cure cannot be
underestimated. Diamyd® is considered to be the world’s furthest developed
Antigen Based Therapy (ABT) for treating the disease. Diamyd® has been used in
clinical studies with more than 1,000 patients and has shown a good safety
profile. In a European Phase III study Diamyd® showed good clinical effect in
several subgroups, and a limited overall 16% efficacy (p=0.10) in preserving
endogenous insulin secretion. To enhance the overall effect, combination
treatments with Diamyd® and other approved agents are being pursued. Diamyd® is
easy to administer in any clinical setting. The potential annual market is
estimated to several billion dollars.

About Diamyd Medical
Diamyd Medical is dedicated to working toward a cure for type 1 diabetes. The
Company’s projects include development of combination regimens with the GAD
-based diabetes vaccine Diamyd® for arresting the destruction of insulin
-producing beta cells. The Company exclusively licenses UCLA-rights to GAD65,
the active ingredient in the vaccine, for which the last patent expires in 2032.
Additionally, the Company exclusively licenses UCLA patents for using GABA for
the treatment of diabetes and other inflammation-related conditions.

Diamyd Medical is one of the major shareholders in the stem cell company
Cellaviva AB, which is establishing a Swedish commercial bank for private family
saving of stem cells in umbilical cord blood and other sources of stem cells.
Stem cells can be expected to be used in Personalized Regenerative Medicine
(PRM), for example, to restore beta cell mass in diabetes patients where
autoimmunity has been arrested.

Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Anders Essen-Möller, President and CEO
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.